[go: up one dir, main page]

FR2990697B1 - Procede d'attenuation d'une bacterie du complexe mycobacterium tuberculosis pour la fabrication d'un vaccin contre la tuberculose - Google Patents

Procede d'attenuation d'une bacterie du complexe mycobacterium tuberculosis pour la fabrication d'un vaccin contre la tuberculose

Info

Publication number
FR2990697B1
FR2990697B1 FR1254623A FR1254623A FR2990697B1 FR 2990697 B1 FR2990697 B1 FR 2990697B1 FR 1254623 A FR1254623 A FR 1254623A FR 1254623 A FR1254623 A FR 1254623A FR 2990697 B1 FR2990697 B1 FR 2990697B1
Authority
FR
France
Prior art keywords
attenuating
bacterium
manufacture
vaccine against
tuberculosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1254623A
Other languages
English (en)
Other versions
FR2990697A1 (fr
Inventor
Michel Drancourt
Otmane Lamrabet
Didier Raoult
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fondation Mediterranee Infection
Original Assignee
Aix Marseille Universite
Assistance Publique Hopitaux de Marseille APHM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aix Marseille Universite, Assistance Publique Hopitaux de Marseille APHM filed Critical Aix Marseille Universite
Priority to FR1254623A priority Critical patent/FR2990697B1/fr
Priority to JP2015513241A priority patent/JP2015518719A/ja
Priority to CN201380024171.1A priority patent/CN104271732A/zh
Priority to EP13729975.6A priority patent/EP2828376A1/fr
Priority to PCT/FR2013/051078 priority patent/WO2013175103A1/fr
Priority to US14/395,727 priority patent/US20150157701A1/en
Publication of FR2990697A1 publication Critical patent/FR2990697A1/fr
Application granted granted Critical
Publication of FR2990697B1 publication Critical patent/FR2990697B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/32—Mycobacterium

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR1254623A 2012-05-21 2012-05-21 Procede d'attenuation d'une bacterie du complexe mycobacterium tuberculosis pour la fabrication d'un vaccin contre la tuberculose Active FR2990697B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR1254623A FR2990697B1 (fr) 2012-05-21 2012-05-21 Procede d'attenuation d'une bacterie du complexe mycobacterium tuberculosis pour la fabrication d'un vaccin contre la tuberculose
JP2015513241A JP2015518719A (ja) 2012-05-21 2013-05-16 結核菌群菌を弱毒化して結核ワクチンを製造する方法
CN201380024171.1A CN104271732A (zh) 2012-05-21 2013-05-16 用于减弱结核分枝杆菌复合群的细菌以生产结核病疫苗的方法
EP13729975.6A EP2828376A1 (fr) 2012-05-21 2013-05-16 Procede d'attenuation d'une bacterie du complexe mycobacterium tuberculosis pour la fabrication d'un vaccin contre la tuberculose
PCT/FR2013/051078 WO2013175103A1 (fr) 2012-05-21 2013-05-16 Procede d'attenuation d'une bacterie du complexe mycobacterium tuberculosis pour la fabrication d'un vaccin contre la tuberculose
US14/395,727 US20150157701A1 (en) 2012-05-21 2013-05-16 Method for attenuating a bacterium of the mycobacterium tuberculosis complex for producing a tuberculosis vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1254623A FR2990697B1 (fr) 2012-05-21 2012-05-21 Procede d'attenuation d'une bacterie du complexe mycobacterium tuberculosis pour la fabrication d'un vaccin contre la tuberculose

Publications (2)

Publication Number Publication Date
FR2990697A1 FR2990697A1 (fr) 2013-11-22
FR2990697B1 true FR2990697B1 (fr) 2015-12-18

Family

ID=47002964

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1254623A Active FR2990697B1 (fr) 2012-05-21 2012-05-21 Procede d'attenuation d'une bacterie du complexe mycobacterium tuberculosis pour la fabrication d'un vaccin contre la tuberculose

Country Status (6)

Country Link
US (1) US20150157701A1 (fr)
EP (1) EP2828376A1 (fr)
JP (1) JP2015518719A (fr)
CN (1) CN104271732A (fr)
FR (1) FR2990697B1 (fr)
WO (1) WO2013175103A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020264258A1 (fr) * 2019-06-28 2020-12-30 United States Government As Represented By The Department Of Veterans Affairs Procédés de production de granulomes et de modèles animaux de sarcoïdose
EP3797791A1 (fr) * 2019-09-26 2021-03-31 Universidad De Zaragoza Efficacité thérapeutique par administration pulmonaire de mycobactéries atténuées vivantes
CN113493788B (zh) * 2021-05-24 2023-06-23 上海晶诺生物科技有限公司 一种分枝杆菌启动子库及其应用
CN118240732B (zh) * 2024-04-01 2024-12-24 华中农业大学 一种结核分枝杆菌Rv3444c-Rv3445c双基因缺失菌株及其制备和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
US20050208078A1 (en) * 2003-11-20 2005-09-22 Hoffman Stephen L Methods for the prevention of malaria
EP3686602A1 (fr) * 2008-09-22 2020-07-29 University of Washington Nanopores msp et procédés associés

Also Published As

Publication number Publication date
CN104271732A (zh) 2015-01-07
US20150157701A1 (en) 2015-06-11
EP2828376A1 (fr) 2015-01-28
WO2013175103A1 (fr) 2013-11-28
FR2990697A1 (fr) 2013-11-22
JP2015518719A (ja) 2015-07-06

Similar Documents

Publication Publication Date Title
IL229582A0 (en) Antibodies against kir for the treatment of inflammatory disorders
EP2934404A4 (fr) Stratifié élastique et procédé de fabrication d'un stratifié élastique.
IL231951A0 (en) Excipients and their use for the preparation of preparations
ZA201305972B (en) Method for the preparation of biphephos
FR2975943B1 (fr) Procede de fabrication d'un panneau d'attenuation acoustique
AP3749A (en) Method for producing pest controlling agent
EP2881183A4 (fr) Dispositifs à vibrations à ultrasons, procédé de fabrication pour dispositifs à vibrations à ultrasons et dispositifs médicaux à ultrasons
GB2498072B (en) Display device and method for manufacturing of the same
PT2715450T (pt) Método de produção de dispositivos microfluídicos monolíticos tridimensionais
EP2787534A4 (fr) Dispositif semiconducteur à grille isolée et procédé pour sa fabrication
EP2681208A4 (fr) Composés antimicrobiens/d'adjuvants et procédés associés
SG11201401508QA (en) Polyisobutylene prepared at high velocity and circulation rate
EP2894032A4 (fr) Procédé de fabrication d'un stratifié
EP2689590A4 (fr) Enceinte de casque anti-bruit
ITBO20110590A1 (it) Procedimento e apparecchiatura per l'estrazione di bava di chiocciola.
ITMI20120169A1 (it) Apparecchiatura sfogliatrice per impiallacciatura.
FR2990697B1 (fr) Procede d'attenuation d'une bacterie du complexe mycobacterium tuberculosis pour la fabrication d'un vaccin contre la tuberculose
DK3284479T3 (da) Fremgangsmåde til fremstilling af medikamenter til bekæmpelse af tumorer
IL229375A0 (en) A method for diagnosing rheumatoid arthritis
EP2770726A4 (fr) Dispositif d'affichage, et procédé de commande d'un appareil photographique du dispositif d'affichage
GB2496389B (en) Method for reducing the phytotoxic effects of N-aryl pyrazole insecticides
EP2797339A4 (fr) Ecouteur et procédé de fabrication de celui-ci
EP2558121A4 (fr) Anticorps anti-epha3 pour le traitement du myélome multiple
ZA201403104B (en) Process for the preparation of higher alcohols
EP2780766A4 (fr) Dispositifs pour quantifier le passage du temps

Legal Events

Date Code Title Description
TP Transmission of property

Owner name: FONDATION MEDITERRANEE INFECTION, FR

Effective date: 20131220

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6